Stocks › ANIK
Anika Therapeutics, Inc.
ANIK·Nasdaq·
United States·USD
$13.23
-0.05 (-0.38%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
ANIK
Anika Therapeutics, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ANIKS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of ANIK by members of U.S. Congress · 12 on record
Whale Activity
Position changes in ANIK reported for 2026-09-30 by 151 institutional filers
- Increased45
- New19
- Held20
- Decreased53
- Closed12
- No prior filing2
| Filer | Shares | Value | Change |
|---|---|---|---|
| Caligan Partners LP | 1.4M | $28.2M | held |
| BlackRock, Inc. | 1.4M | $27.7M | decreased |
| MORGAN STANLEY | 626.4K | $12.3M | increased |
| ACADIAN ASSET MANAGEMENT LLC | 606.5K | $11.9M | held |
| VANGUARD CAPITAL MANAGEMENT LLC | 565.9K | $11.1M | decreased |
| BOOTHBAY FUND MANAGEMENT, LLC | 529.6K | $10.4M | decreased |
| DIMENSIONAL FUND ADVISORS LP | 461.9K | $9.1M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 458.7K | $9.0M | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 419.2K | $8.2M | increased |
| AQR CAPITAL MANAGEMENT LLC | 401.0K | $7.9M | decreased |
| CAPITAL MANAGEMENT CORP /VA | 379.4K | $7.5M | decreased |
| DEUTSCHE BANK AG\ | 352.1K | $6.9M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by ANIK insiders, by quarter · Form 4
Recent Insider Transactions
673 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Fischetti Gary PDirector | Purchase | +1,000 | $20.32 | $20K | Aug 4, 2026 | Form 4 ↗ |
| Fischetti Gary PDirector | Purchase | +1,000 | $20.75 | $21K | Aug 3, 2026 | Form 4 ↗ |
| Fischetti Gary PDirector | Grant / award | +10.4K | $0.00 | $0 | Jun 18, 2026 | Form 4 ↗ |
| HENNEMAN JOHN B IIIDirector | Grant / award | +10.4K | $0.00 | $0 | Jun 18, 2026 | Form 4 ↗ |
| Richard StephenDirector | Grant / award | +10.4K | $0.00 | $0 | Jun 18, 2026 | Form 4 ↗ |
| Capper Joseph HDirector | Grant / award | +10.4K | $0.00 | $0 | Jun 18, 2026 | Form 4 ↗ |
| CONLEY SHERYL LDirector | Grant / award | +10.4K | $0.00 | $0 | Jun 18, 2026 | Form 4 ↗ |
| Griffin Stephen D.President and CEO · Director | Tax withholding | −3,769 | $14.41 | $54K | Jun 3, 2026 | Form 4 ↗ |
| Griffin Stephen D.President and CEO · Director | Option exercise | +12.8K | — | — | Jun 3, 2026 | Form 4 ↗ |
| HENNEMAN JOHN B IIIDirector | Purchase | +5,000 | $14.66 | $73K | May 1, 2026 | Form 4 ↗ |
| Griffin Stephen D.President and CEO · Director | Purchase | +12.2K | $12.29 | $150K | Apr 30, 2026 | Form 4 ↗ |
| Colleran DavidEVP, General Counsel, Corp Sec | Tax withholding | −1,893 | $14.20 | $27K | Mar 15, 2026 | Form 4 ↗ |
| Colleran DavidEVP, General Counsel, Corp Sec | Option exercise | +6,449 | — | — | Mar 15, 2026 | Form 4 ↗ |
| Blanchard Cheryl RDirector | Tax withholding | −12.1K | $14.20 | $172K | Mar 15, 2026 | Form 4 ↗ |
| Blanchard Cheryl RDirector | Option exercise | +25.1K | — | — | Mar 15, 2026 | Form 4 ↗ |
| McLeod IanSVP, CAO & Treasurer | Tax withholding | −781 | $14.20 | $11K | Mar 15, 2026 | Form 4 ↗ |
| McLeod IanSVP, CAO & Treasurer | Option exercise | +2,658 | — | — | Mar 15, 2026 | Form 4 ↗ |
| Colleran DavidEVP, General Counsel, Corp Sec | Tax withholding | −4,168 | $14.20 | $59K | Mar 14, 2026 | Form 4 ↗ |
| Colleran DavidEVP, General Counsel, Corp Sec | Grant / award | +4,694 | $0.00 | $0 | Mar 14, 2026 | Form 4 ↗ |
| Colleran DavidEVP, General Counsel, Corp Sec | Option exercise | +9,388 | — | — | Mar 14, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding ANIK · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 397.8K | $5.8M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 311.3K | $4.6M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 123.7K | $2.4M | 0.01% | Jul 31, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 162.5K | $2.4M | 0.00% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account College Retirement Equities Fund | 142.3K | $2.1M | 0.00% | Jun 30, 2026 |
| U.S. SMALL CAP VALUE PORTFOLIO DFA INVESTMENT DIMENSIONS GROUP INC | 86.7K | $1.7M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF iShares Trust | 104.9K | $1.5M | 0.01% | Jun 30, 2026 |
| Schwab U.S. Small-Cap ETF SCHWAB STRATEGIC TRUST | 66.3K | $1.4M | 0.01% | Aug 31, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 65.8K | $1.4M | 0.00% | Aug 31, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 65.8K | $1.4M | 0.01% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list ANIK's shares (CUSIP 035255108), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming anika therapeutics as client
- JK STRATEGIES, PUBLIC AFFAIRS ,LLCANIKA THERAPEUTICS INC · 2026 Q2$30K
Filing ↗ - JK STRATEGIES, PUBLIC AFFAIRS ,LLCANIKA THERAPEUTICS INC · 2026 Q1$30K
Filing ↗ - JK STRATEGIES, PUBLIC AFFAIRS ,LLCANIKA THERAPEUTICS INC · 2026 Q3$30K
Filing ↗ - JK STRATEGIES, PUBLIC AFFAIRS ,LLCANIKA THERAPEUTICS INC · 2025 Q1 · HCR—
Filing ↗ - KING & SPALDING LLPANIKA THERAPEUTICS, INC. · 2020 Q3—
Filing ↗
Government Contracts
Federal awards to Anika Therapeutics, Inc. · USAspending
No federal contract awards found for Anika Therapeutics, Inc..
U.S. Patents
Recent USPTO applications naming Anika Therapeutics, Inc.
No USPTO patent applications found for Anika Therapeutics, Inc..
Annual Financials
From ANIK's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $112.8M | $119.9M | $120.8M | $113.8M | $147.8M |
| Operating income | -$11.1M | -$5.1M | $844K | $3.7M | $2.6M |
| Net income | -$10.9M | -$56.4M | -$82.7M | -$14.9M | $4.1M |
| Diluted EPS | -$0.76 | -$3.83 | -$5.64 | -$1.02 | $0.28 |
| Operating cash flow | $11.2M | $5.4M | -$1.8M | $4.4M | $8.4M |
| Cash and equivalents | $57.5M | $55.6M | $68.7M | $86.3M | $94.4M |
| Total assets | $190.3M | $202.7M | $270.6M | $349.1M | $347.5M |
| Shareholders' equity | $143.5M | $154.0M | $212.3M | $285.6M | $287.1M |
As Anika Therapeutics, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 3, 2026 ↗
Stock Splits
Every split and reverse split in the price history
No stock splits in ANIK's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 9.01Results of operationsNov 6, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 29, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.03, 9.01Material agreement · Direct financial obligationJul 14, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 23, 2026
EDGAR ↗
About Anika Therapeutics, Inc.
From SEC EDGAR company records
Industry (SIC 3841)Surgical & Medical Instruments & Apparatus
SectorHealthcare
HeadquartersBEDFORD, MA
IncorporatedDE
SEC CIK0000898437 ↗
Former namesANIKA THERAPEUTICS INC, ANIKA RESEARCH INC


